Benfotiamine is the molecule longevity researchers reached for when plain vitamin B1 turned out to be nearly useless as a supplement — its absorption saturates at just a few milligrams, so most of a pill passes straight through. The fix, developed in Japan in the 1960s, was to attach a fat-soluble tail to thiamine, creating a form that floods cells with three to five times more active vitamin B1. In the early 2000s, endocrinologist Michael Brownlee’s “unifying mechanism” of diabetic complications handed benfotiamine a precise job: activate an enzyme called transketolase to shunt excess sugar away from the pathways that build AGEs — the sticky, cross-linking proteins at the heart of age-related tissue damage. Two decades later, benfotiamine’s story is a masterclass in the gap between an elegant mechanism and a messy clinical reality.
📋 Simple Summary
Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) that your body absorbs much better than regular thiamine. It works by activating an enzyme called transketolase, which shunts excess sugar away from the pathways that create “AGEs” — advanced glycation end products, the sticky proteins that damage nerves, blood vessels, and brain tissue as we age. In mice engineered to develop Alzheimer’s-like brain tangles, benfotiamine extended lifespan and protected brain cells. But in people, the two biggest clinical trials — one for diabetic nerve damage (2026) and one for Alzheimer’s (2020) — both missed their primary goals. Benfotiamine is remarkably safe and has a real, well-understood mechanism, but the human evidence has not yet caught up to the theory. This page lays out exactly what the science shows, what dose the trials used, and who might still benefit.
The detailed breakdown continues below for those who want the full science.
Published: August 15, 2026
Evidence Tier: 🥉 Bronze — compelling mechanism and strong mouse data, but the definitive human trials have not delivered
Category: 💊 Supplements & Compounds
⚖️ At a Glance: Pros & Cons
⚠️ We are researchers, not doctors. Nothing on this page is medical advice. Talk to your doctor before taking any supplement. The information below is for education only.
✅ Pros (What the Evidence Supports)
- Strongest benefit: Activates transketolase, diverting excess sugar away from four damaging pathways — the best-validated way to block AGE (glycation) formation.
- Brain protection: In mice with Alzheimer’s-like tau tangles, benfotiamine extended lifespan, cut brain tangles, and reduced glycated tau — and it uniquely activates the Nrf2 antioxidant pathway that plain thiamine does not.
- Safety: Extremely well tolerated — a Phase I trial found side effects matched placebo even at 1,200 mg/day.
- Real human signal in Alzheimer’s: A 12-month trial cut worsening on a dementia scale by 77% (statistically significant) and significantly lowered blood AGEs.
❌ Cons (What the Evidence Doesn’t Support or Warns About)
- Biggest limitation: The 2026 BOND trial — for diabetic neuropathy, the condition benfotiamine is most famous for — found no benefit on its primary endpoint after 12 months.
- Alzheimer’s primary endpoint missed: The 2020 Phase IIa trial’s main cognitive score improved by 43% but fell short of statistical significance (p = 0.125).
- No glycemic benefit: A 2022 meta-analysis of six trials found benfotiamine/thiamine did not lower HbA1c or blood sugar.
- Who should avoid: Pregnancy and breastfeeding (no data), and anyone on diabetes medication should coordinate with their doctor first.
What Is Benfotiamine?
Benfotiamine is a synthetic, fat-soluble derivative of thiamine (vitamin B1). Chemically, it is an S-acyl thiamine — a member of a family called the allithiamines, developed in Japan in the 1960s specifically to solve thiamine’s poor absorption. Regular thiamine hydrochloride saturates its intestinal transporter at around 5 mg per dose, so anything above that is mostly wasted; benfotiamine bypasses that bottleneck entirely, raising blood and tissue thiamine levels 3.6 to 5 times higher than an equivalent dose of plain thiamine (PMID 29863274, 38034619).
The crucial point is that benfotiamine is not simply “better thiamine.” It does at least one thing thiamine does not: activate the Nrf2/ARE antioxidant pathway, the cell’s built-in defense program against oxidative stress. In a 2018 study, benfotiamine and its breakdown products — but not thiamine itself — bound to a protein called Keap1 and switched on a battery of protective genes (PMID 29860433). That distinction matters whenever someone tells you “just take a B-complex.”
How It Works
Benfotiamine’s central mechanism is transketolase activation, and it traces directly to the biology of blood sugar. When glucose floods a cell, the excess is diverted down four damaging side-branches: (1) AGE formation, (2) the hexosamine pathway, (3) protein kinase C (PKC) activation, and (4) the polyol pathway. These four routes — first linked together by Michael Brownlee’s “unifying mechanism” of diabetic complications — drive the nerve, kidney, eye, and blood-vessel damage seen in diabetes, and they contribute to glycation-related aging in everyone, not just diabetics.
Transketolase is the enzyme that redirects those excess sugar molecules into the harmless pentose phosphate pathway, which makes NADPH (a key antioxidant currency) and ribose. Transketolase needs thiamine pyrophosphate (TPP) as its cofactor. Benfotiamine, by dramatically raising TPP inside cells, revs up transketolase and shunts sugar away from the four damaging pathways — which is why it reduces AGE formation (PMID 29863274, 28541026). One striking demonstration: in diabetic rats, benfotiamine lowered D-ribose and glycated hemoglobin (HbA1c) by activating transketolase (PMID 29033370).
The second, more recent mechanism is the Nrf2/ARE antioxidant pathway. Benfotiamine and its metabolites bind Keap1, freeing Nrf2 to turn on dozens of antioxidant and detox genes — an effect plain thiamine does not have (PMID 29860433). This gives benfotiamine a two-punch profile: it reduces the formation of damage (AGEs) and boosts the cell’s cleanup response to damage (Nrf2).
The Longevity Connection
🩸 Glycation (AGEs) — the direct anti-aging mechanism. Advanced glycation end products accumulate throughout life as sugar binds to proteins and cross-links them, stiffening arteries, clouding the eye lens, and impairing kidney, nerve, and skin function. Benfotiamine is one of the few oral compounds that directly reduces AGE formation. In the Alzheimer’s Phase IIa trial, benfotiamine significantly lowered blood AGE levels over 12 months (p = 0.044) — direct human confirmation that the mechanism works in people (PMID 33074237).
🧠 Brain and Alzheimer’s — the strongest preclinical case. In mice engineered to develop Alzheimer’s-like amyloid plaques, benfotiamine rescued cognitive deficits and reduced the amyloid burden. In a separate tauopathy mouse model (P301S), chronic benfotiamine increased lifespan, reduced tau tangles and glycated tau, and prevented motor-neuron death (PMID 29860433). The human side is more mixed: the 2020 Phase IIa trial is detailed below, and the larger BenfoTeam trial (406 participants, 72 weeks, 600 vs 1,200 mg) is still running (PMID 38809849, NCT06223360).
🦶 Nerve health (diabetic neuropathy) — the classic use, now questioned. Benfotiamine is widely sold for nerve pain and tingling in diabetes. Early short-term studies were encouraging, but the long-term picture changed in 2026 (see the BOND study below).
💪 Muscle. In a mouse model of Duchenne muscular dystrophy, benfotiamine reduced muscle inflammation and fibrosis and improved grip strength and exercise capacity (PMID 38710523).
🫀 Heart and metabolism. Recent mouse studies show benfotiamine blunts oxidative-stress-driven heart damage from noise exposure (PMID 40582321), and 2025 work proposes thiamine acts as a natural modulator of the metabolic receptor PPARγ (PMID 41368574). A 2022 meta-analysis, however, found no meaningful effect on blood sugar or HbA1c (PMID 36008064).
Key Studies
| Study | Design | Key Finding |
|---|---|---|
| Tapias 2018 (PMID 29860433) | P301S tauopathy mice | Benfotiamine increased lifespan, reduced tau tangles and glycated tau, and activated the Nrf2/ARE pathway (unlike thiamine itself). |
| Gibson 2020 (PMID 33074237) | Phase IIa RCT, n = 70, 12 months | CDR worsening 77% lower (p = 0.034) and AGEs reduced (p = 0.044); primary ADAS-Cog test missed significance (p = 0.125). |
| Ziegler 2026 — BOND (PMID 41571333) | Phase II RCT, n = 57, 300 mg 2×/day, 12 months | No effect on corneal nerve fiber length or any neurophysiological measure in diabetic neuropathy; only a symptom score trended better (p = 0.098). |
| Feldman 2024 — BenfoTeam (PMID 38809849) | Seamless Phase 2A–2B, n = 406, 72 weeks | Ongoing trial testing 600 vs 1,200 mg in early Alzheimer’s; results pending. |
| Sheng 2021 (PMID 33727798) | Phase I SAD/MAD, 150–1,200 mg | Safe and well tolerated; adverse events similar to placebo; mild, transient ALT elevation was the most common drug-related event. |
| Muley 2022 (PMID 36008064) | Meta-analysis, 6 trials, n = 364 | No significant effect on HbA1c, fasting glucose, or post-meal glucose; small HDL increase and triglyceride reduction at 120 mg. |
| Chen 2017 (PMID 29033370) | Diabetic rats + human samples | Benfotiamine-activated transketolase lowered D-ribose and HbA1c, confirming the AGE-blocking mechanism. |
| Coles 2024 (PMID 38710523) | mdx mice (Duchenne model) | Reduced muscle inflammation and fibrosis; improved grip strength and exercise capacity. |
Dosing and Safety
There is no “longevity dose” of benfotiamine — no trial has tested it for extending human lifespan. The doses below come from disease trials and safety studies.
| Context | Dose | Notes |
|---|---|---|
| Diabetic neuropathy trials | 300 mg twice daily (600 mg total) | The BOND study dose; well tolerated but no clear benefit. |
| Alzheimer’s Phase IIa | 600 mg/day (300 mg 2×) | Produced the significant AGE and CDR signals. |
| BenfoTeam trial (ongoing) | 600 mg or 1,200 mg/day | Higher dose being tested for safety/efficacy in early AD. |
| Phase I safety ceiling | Up to 1,200 mg/day | Well tolerated; no serious adverse events. |
| Common supplement range | 150–600 mg/day | Fat-soluble, so take with a meal that contains some fat. |
Safety notes:
- Excellent safety record. In the Phase I study, adverse events were no more common with benfotiamine than with placebo, even at 1,200 mg/day. The most commonly reported drug-related events were a transient rise in the liver enzyme ALT and white blood cells in the urine — both mild and self-limiting (PMID 33727798).
- No established toxic upper limit. Unlike many fat-soluble vitamins, benfotiamine does not accumulate dangerously.
- Drug interactions are minimal. There is a theoretical possibility that benfotiamine could add to glucose-lowering medications, but the meta-analysis found no meaningful blood-sugar effect (PMID 36008064).
- Limited long-term data. The longest human trials run 12 months; safety beyond a year is inferred, not proven.
❓ Common Questions About Benfotiamine
What is benfotiamine and how does it work?
Benfotiamine is a fat-soluble form of vitamin B1 (thiamine) that your body absorbs far better than regular thiamine. It activates an enzyme called transketolase, which shunts excess sugar away from the pathways that build “AGEs” — sticky proteins that damage nerves, blood vessels, and brain tissue as we age. It also switches on Nrf2, the cell’s built-in antioxidant defense, something plain thiamine does not do.
What does the evidence actually show?
The evidence is strong in cells and mice — benfotiamine extended lifespan in mice with Alzheimer’s-like brain tangles and reduced those tangles. In humans it is weaker: the big 2026 trial for diabetic nerve damage found no benefit, and the 2020 Alzheimer’s trial’s main cognitive test just missed significance, though it did slow functional decline on a secondary measure and lower AGEs. Overall this is 🥉 Bronze — a real mechanism, but human trials have not yet delivered.
What’s the right dose?
Clinical trials used 300 mg twice a day (600 mg total) for nerve damage and Alzheimer’s, and a Phase I safety study found up to 1,200 mg a day well tolerated. Because benfotiamine is fat-soluble, take it with a meal. Most brands sell 150–300 mg capsules, and 300–600 mg a day is a common starting point — but there is no proven “longevity dose.”
What are the risks and side effects?
Benfotiamine is remarkably safe. In a Phase I trial, side effects matched placebo even at 1,200 mg a day. The most common issues are mild stomach upset and, occasionally, a temporary rise in the liver enzyme ALT. No serious adverse events have been linked to benfotiamine in clinical trials, and there is no established toxic upper limit.
Who should avoid it?
Pregnant or breastfeeding women should avoid benfotiamine — there is simply no safety data. People on diabetes medication should talk to their doctor first, since benfotiamine affects glucose handling even though trials found no meaningful blood-sugar change. Anyone with a rare allergy to thiamine should avoid it. As always, check with your doctor before starting any supplement.
The Bottom Line
The evidence hierarchy is clear: mechanism (strong) > mouse data (positive, including lifespan) > human trials (mixed to negative). Benfotiamine has one of the cleanest mechanistic stories in the supplement world — a direct, measurable way to block the formation of AGEs, the sugar-driven protein damage that accumulates with age — plus an Nrf2 antioxidant effect that plain thiamine lacks. In mice, it extends lifespan and protects brain cells. That is a genuinely promising profile.
But the clinical reality has been humbling. The 2026 BOND trial found no benefit for diabetic neuropathy, the exact condition benfotiamine is most marketed for. The 2020 Alzheimer’s trial produced encouraging but statistically muddled results, and the definitive BenfoTeam trial is still years from an answer. We rate benfotiamine 🥉 Bronze overall: worth understanding, not worth betting your health budget on — at least until BenfoTeam reports.
Who it’s for: people with diabetes or prediabetes who want to address the glycation axis under a doctor’s supervision, and longevity enthusiasts drawn to the AGE-blocking mechanism who accept that the human proof is not there yet. For everyone else, the free, proven ways to reduce AGE formation — keeping blood sugar in check, exercise, and not overcooking food — deliver more certainty for zero cost.
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Benfotiamine is not approved to treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement, especially if you have diabetes, take prescription medication, or are pregnant or breastfeeding. Read our full disclaimer →
Sources
- Tapias V, et al. Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet. 2018. PMID 29860433
- Gibson GE, et al. Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis. 2020. PMID 33074237
- Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy (BOND study). BMJ Open Diabetes Res Care. 2026. PMID 41571333
- Feldman HH, et al. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial of benfotiamine in early Alzheimer’s disease (BenfoTeam). PLoS One. 2024. PMID 38809849
- Sheng L, et al. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects. Drug Des Devel Ther. 2021. PMID 33727798
- Muley A, et al. Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2022. PMID 36008064
- Raj V, et al. Therapeutic potential of benfotiamine and its molecular targets. Eur Rev Med Pharmacol Sci. 2018. PMID 29863274
- Chen Y, et al. D-Ribose as a Contributor to Glycated Haemoglobin. EBioMedicine. 2017. PMID 29033370
- Coles C, et al. Benfotiamine improves dystrophic pathology and exercise capacity in mdx mice by reducing inflammation and fibrosis. Hum Mol Genet. 2024. PMID 38710523
- Bozic I, Lavrnja I. Thiamine and benfotiamine: Focus on their therapeutic potential. Heliyon. 2023. PMID 38034619
- Saxena R, et al. Unravelling advanced glycation end products as emerging therapeutic targets in diabetic retinopathy management. Eur J Ophthalmol. 2025. PMID 40123240
- Panati K, et al. Thiamine as a putative natural modulator of PPARγ. Front Pharmacol. 2025. PMID 41368574
- Beltramo E, et al. Thiamine and diabetes: back to the future? Acta Diabetol. 2021. PMID 34091762
- Motamedzadeh A, et al. Potential of Benfotiamine in the treatment of neuropsychological disorders. Mol Biol Rep. 2025. PMID 41160288
- Karaganis S, Song X. B vitamins as a treatment for diabetic pain and neuropathy. J Clin Pharm Ther. 2021. PMID 33565138